Attached To Antibody Or Antibody Fragment Or Immunoglobulin; Derivative Patents (Class 424/1.49)
-
Publication number: 20120230912Abstract: The invention pertains to a method of measuring A? protofibrils in a sample. The method includes the steps of (a) providing a labeled monoclonal antibody or fragment thereof that binds wildtype A? 42/40 protofibril and A?42/40 Arc protofibril and has no or little cross-reactivity to A? 42/40 monomers with an agent that generates a measurable signal, (b) contacting said labeled antibody or fragment thereof with the fluid or tissue having or suspected of comprising A? protofibrils, and (c) measuring the amount of protofibrils bound to the antibody by measuring the signal generated by the agent.Type: ApplicationFiled: December 23, 2011Publication date: September 13, 2012Applicant: BioArctic Neuroscience ABInventors: Pär Gellerfors, Lars Lannfelt
-
Patent number: 8263039Abstract: Use of DKK-1 protein or the nucleic acid sequence in preparation of cancer diagnostic agents or kits, method to detect liver cancer with the monoclonal antibody thereof, the kit comprising anti-DKK-1 antibody or protein specific nucleic acid probes, together with a label, and method to detecting specific DKK-1 protein expression are disclosed.Type: GrantFiled: November 11, 2008Date of Patent: September 11, 2012Assignee: Shanghai Cancer InstituteInventors: Wenxin Qin, Haitao Zhang, Yanjun Yu, Haiyan You, Shengli Yang, Jianren Gu, Gang Huang, Shile Sheng, Tao Chen
-
Publication number: 20120225013Abstract: The invention provides anti-mesothelin antibodies and immunoconjugates and methods of using the same.Type: ApplicationFiled: December 19, 2011Publication date: September 6, 2012Inventors: Mark Dennis, Suzanna J. Scales, Susan D. Spencer, Yin Zhang
-
Publication number: 20120225014Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies.Type: ApplicationFiled: May 14, 2012Publication date: September 6, 2012Applicants: Pfizer Inc., Amgen Fremont Inc.Inventors: Vahe Bedian, Ronald P. Gladue, Jose Corvalan, Xiao-Chi Jia, Xiao Feng
-
Patent number: 8257682Abstract: This disclosure relates to compositions for delivering agents to a subject, and in particular, to compositions for delivery of therapeutic agents or diagnostic agents in the presence or absence of targeting moieties. In part, this disclosure relates to compositions comprising a hydrophobic group with a first end and a second end, a first metal binding domain linked to the hydrophobic group, a metal ion capable of being chelated to the first metal binding domain, and an agent linked to a second metal binding domain capable of chelating to the metal ion.Type: GrantFiled: August 31, 2009Date of Patent: September 4, 2012Assignee: PharmaIn CorporationInventors: Elijah M. Bolotin, Gerardo M. Castillo
-
Patent number: 8252267Abstract: The present invention relates to novel sequences for use in detection, diagnosis and treatment of diseases, including cancer. The invention provides novel splice products of human DKKL-1 gene. The present invention provides methods of using polynucleotides having the novel splice products of the human DKKL-1 sequences, their corresponding gene products and modulators of the DKKL-1 splice products for the detection, diagnosis, prevention and/or treatment of associated cancers.Type: GrantFiled: March 30, 2006Date of Patent: August 28, 2012Assignee: Sagres Discovery, Inc.Inventors: Albert Lai, Robert Booher
-
Publication number: 20120213699Abstract: Anti-ACE single chain fragment antibodies are disclosed. The present invention relates to using these antibodies, and polymers thereof, in methods for detecting, diagnosing, prognosing, preventing, or treating diseases associated with ACE expressing tissue.Type: ApplicationFiled: May 3, 2012Publication date: August 23, 2012Applicant: The Board of Trustees of the University of IllinoisInventors: Irina Balyasnikova, Sergei Danilov
-
Publication number: 20120207673Abstract: The present disclosure provides an isolated protein comprising an antibody heavy chain variable region (VH) comprising a negatively charged amino acid at position 28 and/or 31 and/or 32 and/or 33 and/or 35 according to the numbering system of Kabat, the protein capable of binding specifically to an antigen.Type: ApplicationFiled: October 25, 2010Publication date: August 16, 2012Inventors: Daniel Christ, Kip Dudgeon
-
Publication number: 20120207672Abstract: The present invention refers to the detection of bone metastases in renal cell carcinoma (RCC) and suitable reagents therefore using a 124 I-labelled antibody or antigen-binding fragment thereof directed against carbonic anhydrase IX.Type: ApplicationFiled: September 15, 2010Publication date: August 16, 2012Applicant: WILEX AGInventors: Roman Bartz, Robert Uzzo, David Chen
-
Publication number: 20120201751Abstract: This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB/chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays, which utilize the CDMAB of the instant invention. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.Type: ApplicationFiled: December 5, 2011Publication date: August 9, 2012Applicant: HOFFMANN-LA ROCHE INC.Inventors: David S. F. Young, Helen P. Findlay, Susan E. Hahn, Lisa M. Cechetto, Fortunata McConkey, Maximiliano Vasquez
-
Publication number: 20120201750Abstract: The present invention relates to methods for predicting and evaluating metastasis of solid cancers, such as melanoma, in a subject by measuring serum biomarkers associated with a metastatic phenotype. In particular, the present invention provides a serum gene expression signature that is different between highly aggressive and more metastatic versus less aggressive and less metastatic melanomas by quantitatively measuring the levels of, inter alia, lymphoid-specific helicase (HELLS) and condensing complex subunit 2 (NCAPH) transcripts in a subject.Type: ApplicationFiled: September 20, 2011Publication date: August 9, 2012Inventor: Bungwoo Ryu
-
Publication number: 20120195829Abstract: The present invention is directed to a method of identifying tissue targeting domains. In particular, the invention relates to methods for identifying a polynucleotide encoding a targeting domain which directs tumor cell localization to secondary sites, to methods of utilizing the polynucleotide and corresponding polypeptide or fragments thereof and compositions comprising the same.Type: ApplicationFiled: February 2, 2012Publication date: August 2, 2012Applicant: Georgetown UniversityInventors: Anton Wellstein, Kevin J. McDonnell, Justinian R. Ngaiza
-
Publication number: 20120195830Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.Type: ApplicationFiled: March 21, 2012Publication date: August 2, 2012Applicants: JOHANNES GUTENBERG-UNIVERSITAT MAINZ, GANYMED PHARMACEUTICALS AGInventors: Ugur Sahin, Özlem Türeci, Dirk Usener, Stefan Fritz, Christoph Uherek, Gunda Brandenburg, Harald-Gerhard Geppert, Anja Kristina Schröder, Phillippe Thiel
-
Publication number: 20120195831Abstract: The present invention relates to Her3 specific antibodies, preferably fully human or humanized antibodies and antigen-binding portions thereof. Nucleic acid molecules encoding the Her3 antibodies as well as methods of use thereof are also disclosed. Also included are pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for treatment and diagnosis of pathological hyperproliferative oncogenic disorders associated with aberrant expression of Her3 or Her2 including aberrant activation of each of these receptors.Type: ApplicationFiled: October 7, 2010Publication date: August 2, 2012Inventors: Ningyan Zhang, Hans Huber
-
Publication number: 20120189541Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Type: ApplicationFiled: December 20, 2011Publication date: July 26, 2012Applicant: ABBOTT LABORATORIESInventor: Chengbin Wu
-
Publication number: 20120189542Abstract: The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases. In more particular embodiments, the humanized anti-CD19 antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels. In a particularly preferred embodiment, the substitutions comprise a Ser91Phe substitution in the hA19 VH sequence.Type: ApplicationFiled: February 16, 2012Publication date: July 26, 2012Applicant: IMMUNOMEDICS, INC.Inventors: Hans J. Hansen, Zhengxing Qu, David M. Goldenberg
-
Publication number: 20120183472Abstract: B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including chemotherapy and radiotherapy, have limited utility due to toxic side effects. Immunotherapy with anti-CD20 antibodies have also provided limited success. The use of antibodies that bind with the CD22 or CD19 antigen, however, provides an effective means to treat B-cell malignancies such as indolent and aggressive forms of B-cell lymphomas, and acute and chronic forms of lymphatic leukemias. Moreover, immunotherapy with anti-CD22 and/or anti-CD19 antibodies requires comparatively low doses of antibody protein, and can be used effectively in multimodal therapies.Type: ApplicationFiled: December 21, 2011Publication date: July 19, 2012Applicant: IMMUNOMEDICS, INC.Inventor: David M. Goldenberg
-
Publication number: 20120183473Abstract: A therapeutically active ingredient is administered to the human or animal body. The active ingredient contains an ?-hydroxy acid, an ?-amino acid, a peptide or a protein, the component being radiolabeled with 11C and the radioactive atom replacing the C atom of the carboxyl group or of a peptide bond in the a position. The labeled therapeutically active ingredient which is chemically identical to the active ingredient to be used for therapeutic purposes can be advantageously used in tests which allow a dispersion of the active ingredient to be tested in tissue samples or in the human or animal body by positron emission tomography. The complementary information can for example help to accelerate the approval procedure for medicaments.Type: ApplicationFiled: July 13, 2010Publication date: July 19, 2012Applicant: SIEMENS AKTIENGESELLSCHAFTInventors: Oliver Lade, Arno Steckenborn
-
Patent number: 8221719Abstract: This invention relates to a group of novel chelating agents, novel chelates, biomolecules labeled with said chelates or chelating agents as well as solid supports conjugated with said chelates, chelating agents or labeled biomolecules. Especially the invention relates to novel chelating agents useful in solid phase synthesis of oligonucleotides or oligopeptides and the oligonucleotides and oligopeptides so obtained.Type: GrantFiled: September 5, 2008Date of Patent: July 17, 2012Assignee: Wallac OyInventors: Jari Peuralahti, Jari Hovinen, Janne Ketola, Lassi Jaakkola, Veli-Matti Mukkala, Päivi Liitti
-
Publication number: 20120177568Abstract: Meditope variants and methods for their use are provided herein. A meditope variant as described herein comprises a peptide having a sequence CQFDLSTRRLKC (SEQ ID NO:1) or CQYNLSSRALKC (SEQ ID NO:2) that has one or more modifications at of least one amino acid residue of the sequence. Multivalent meditope variant tethering entities are also provided. Such entities may include two or more meditopes coupled via a long linker, multivalent scaffold, biotin-streptavidin, or IgG Fc domain. Further, methods of treating, imaging or diagnosing a disease or condition are provided. Such methods may include administering a therapeutically effective amount of a pharmaceutical composition to a subject, the pharmaceutical compound comprising an antibody-meditope complex; a multivalent tethering agent in combination with a monoclonal antibody or functional fragment thereof; or a combination thereof.Type: ApplicationFiled: October 10, 2011Publication date: July 12, 2012Inventors: John C. WILLIAMS, David A. Horne, Yuelong Ma, Heng Wei Chen
-
Publication number: 20120171115Abstract: The present invention provides an isolated protein comprising an immunoglobulin variable region comprising at least two cysteine residues positioned within framework region (FR) 2 and/or at least two cysteine residues positioned within framework region (FR3), wherein if at least two of the cysteine residues in FR2 and/or FR3 are not conjugated to a compound then an intra-framework disulphide bond is capable of forming between the cysteine residues. Preferably the protein comprises an immunoglobulin heavy chain variable region (VH) and an immunoglobulin light chain variable region (VL), wherein at least one of the variable regions comprises the two cysteine residues. The present invention also provides conjugates of the protein and another compound.Type: ApplicationFiled: December 23, 2010Publication date: July 5, 2012Applicant: AVIPEP Pty LimitedInventors: Peter J. Hudson, Debra Tamvakis, Michael Paul Wheatcroft, Fabio Turatti
-
Publication number: 20120164067Abstract: NGF antagonists including antibodies and antibody fragments thereof having binding specificity to human Nerve Growth Factor (“NGF”), and methods of treating pain. Methods of treating pain or eliciting an analgesic effect in an individual comprising administering an effective amount of an NGF antagonist inhibits the association of NGF with TrkA without inhibiting the association of NGF with p75. The methods may further comprise administering an effective amount of a second anti-human NGF antibody or fragment thereof which inhibits the association of NGF with p75, that may further also inhibit the association of NGF with TrkA.Type: ApplicationFiled: December 1, 2011Publication date: June 28, 2012Inventors: John A. Latham, Ethan W. Ojala, Jeffrey T.L. Smith, Benjamin H. Dutzar, Leon F. Garcia-Martinez
-
Publication number: 20120164068Abstract: The present invention provides an isolated protein comprising an immunoglobulin variable region comprising at least two cysteine residues positioned within framework region 1 such that if at least two of the cysteine residues are not conjugated to another compound a disulphide bond forms between the cysteine residues. Preferably the protein comprises an immunoglobulin heavy chain variable region and an immunoglobulin light chain variable region, wherein at least one of the variable regions comprises the two cysteine residues. The present invention also provides a protein that binds to TAG72. The present invention also provides conjugates of the protein and another compound.Type: ApplicationFiled: July 2, 2010Publication date: June 28, 2012Inventors: Peter John Hudson, Paul Robert Sanders, Debra Tamvakis, Fabio Turatti, Michael Paul Wheatcroft, David Leong
-
Publication number: 20120164066Abstract: Disclosed herein are recombinant protein scaffolds and recombinant multifunctional protein scaffolds for use in producing antigen-binding proteins In addition, nucleic acids encoding such recombinant protein scaffolds, recombinant multifunctional protein scaffolds, and antigen-binding proteins are provided Vectors and cells useful for expression of the described proteins are also provided, as are methods of use.Type: ApplicationFiled: March 31, 2010Publication date: June 28, 2012Applicant: The Trustees of the University of PennsylvaniaInventors: Mark I. Greene, Hongtao Zhang, Xiaomin Song, Ramachandran Murali, Masahide Tone
-
Patent number: 8206711Abstract: Chronic Lymphocytic Leukemia (CLL) may be treated with antibodies directed against the CD20 antigen.Type: GrantFiled: December 2, 2009Date of Patent: June 26, 2012Assignees: Biogen Idec Inc., Genentech, Inc.Inventors: Christine A. White, Antonio J. Grillo-Lopez, John G. Curd, Susan Desmond-Hellmann
-
Publication number: 20120156130Abstract: Described herein are materials and methods for using a HER3 binding agent for prostate treatment. The HER3 binding agent can be, for example, an antibody, and can be used to treat conditions such as benign prostate hyperplasia (BPH) and prostate cancer.Type: ApplicationFiled: August 8, 2011Publication date: June 21, 2012Inventors: Thore HETTMANN, Daniel J. Freeman, Robert Radinsky, Darrin M. Beaupre
-
Publication number: 20120156129Abstract: The present invention relates to the use of VEGF antagonists and a novel anti-?5?1 antibody for treating cancer and inhibiting angiogenesis and/or vascular permeability, including inhibiting abnormal angiogenesis in diseases. The present invention also relates to compositions and kits comprising novel anti-?5?1 antibodies and methods of making and using them.Type: ApplicationFiled: May 20, 2011Publication date: June 21, 2012Applicant: Genentech, Inc.Inventors: Wei-Ching Liang, Gregory D. Plowman, Yan Wu, Weilan Ye
-
Patent number: 8202509Abstract: The present application discloses compositions and methods of synthesis and use of 68Ga, 18F or 19F labeled molecules of use in PET or MRI imaging. Preferably, the 18F or 19F is conjugated to a targeting molecule by formation of a complex with a group IIIA metal and binding of the complex to a chelating moiety, which may be directly or indirectly attached to the targeting molecule. In other embodiments, the 68Ga, 18F or 19F labeled moiety may comprise a targetable construct used in combination with a bispecific antibody to target a disease-associated antigen. In more preferred embodiments, a chelating moiety or targetable construct may be conjugated to a targeting molecule, such as an antibody or antibody fragment.Type: GrantFiled: December 2, 2010Date of Patent: June 19, 2012Assignee: Immunomedics, Inc.Inventors: William J. McBride, Christopher A. D'Souza, David M. Goldenberg
-
Publication number: 20120148490Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for NGF. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-NGF antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-NGF antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-NGF antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with NGF.Type: ApplicationFiled: December 1, 2011Publication date: June 14, 2012Inventors: Benjamin H. Dutzar, Brian R. Kovacevich, Patricia Dianne NcNeill, Danielle M. Mitchell, Ethan W. Ojala, Pei Fan, Jens Billgren, Erica A. Stewart, Corinne C. Akatsuka, Betty Yu-Ching Chang, John A. Latham, Leon F. Garcia-Martinez
-
Publication number: 20120141375Abstract: Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The antibodies show novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. Preferably, the antibodies bind to pancreatic cancer mucins such as MUC1 or MUC5ac and are of use for the detection and diagnosis of early stage pancreatic cancer. In more preferred embodiments, the anti-pancreatic cancer antibodies can be used for immunoassay of serum samples, wherein the immunoassay detects a marker for early stage pancreatic cancer in serum. Most preferably, the serum is extracted with an organic phase, such as butanol, before immunoassay. Alternatively, immunoassay with PAM4 and anti-CA19.9 antibodies may be utilized to improve sensitivity for pancreatic cancer.Type: ApplicationFiled: February 13, 2012Publication date: June 7, 2012Applicant: IMMUNOMEDICS, INC.Inventors: David V. Gold, David M. Goldenberg
-
Publication number: 20120141372Abstract: This invention relates to monovalent and multivalent, monospecific binding proteins and to multivalent, multispecific binding proteins. One embodiment of these binding proteins has one or more binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these binding proteins has two or more binding sites where each binding site has affinity towards different epitopes on a target antigen or has affinity towards either a target antigen or a hapten. The present invention further relates to recombinant vectors useful for the expression of these functional binding proteins in a host. More specifically, the present invention relates to the tumor-associated antigen binding protein designated RS7, and other EGP-1 binding-proteins. The invention further relates to humanized, human and chimeric RS7 antigen binding proteins, and the use of such binding proteins in diagnosis and therapy.Type: ApplicationFiled: November 10, 2011Publication date: June 7, 2012Applicant: IMMUNOMEDICS, INC.Inventors: Serengulam V. Govindan, Zhengxing Qu, Hans J. Hansen, David M. Goldenberg
-
Publication number: 20120141373Abstract: The disclosure relates to protease-binding agent specific for a protease. The agent may be an antibody capable of specifically binding and inhibiting a protease, such as a P1-Arg-specific protease. The disclosure also provides methods of producing, and compositions comprising the subject agent. Methods and kits related to the protease-binding agent find use in protection against, detection, diagnosing, treating cancer and infections due to pathogens containing active proteases.Type: ApplicationFiled: May 4, 2010Publication date: June 7, 2012Inventors: Charles S. Craik, Eric L. Schneider
-
Publication number: 20120141374Abstract: Anti-HEPSIN monoclonal antibodies, and methods for using the antibodies, are provided.Type: ApplicationFiled: January 20, 2012Publication date: June 7, 2012Applicant: Genentech, Inc.Inventors: Daniel K. Kirchhofer, Rajesh Vij
-
Publication number: 20120128584Abstract: The present invention relates to anti-CDH3 antibodies, which can be labeled with a radioisotope. Moreover, the present invention provides methods and pharmaceutical compositions that comprise an anti-CDH3 antibody as an active ingredient. Since CDH3 is strongly expressed in pancreatic, lung, colon, prostate, breast, gastric or liver cancer cells, the present invention is useful in pancreatic, lung, colon, prostate, breast, gastric or liver cancer therapies.Type: ApplicationFiled: June 30, 2009Publication date: May 24, 2012Applicant: Oncotherapy Science, Inc.Inventors: Akira Togashi, Masakazu Katsu, Megumi Takayanagi, Hiroki Yoshioka, Pohsing Ng, Yasuhiro Shiba, Yusuke Nakamura, Keigo Endo
-
Publication number: 20120121505Abstract: The present application provides novel binding proteins, including human binding proteins that specifically bind to the human ErbB2.Type: ApplicationFiled: January 12, 2012Publication date: May 17, 2012Inventors: Davinder Singh Gill, Laird Bloom, Maximillian T. Follettie, Fionnuala McAleese, Sreekumar Kodangattil, John Francis DiJoseph, Nitin K. Damle, Peter R. Baum, Peter A. Thompson, John C. Kumer, Alan F. Wahl, Paul A. Algate, Sateesh Kumar Natarajan
-
Publication number: 20120121506Abstract: Antibodies which bind an antigen of the bone marrow neovasculature in leukaemia patients, for use in treatment and diagnosis of leukaemia, in particular the treatment and diagnosis of acute myeloid leukaemia (AML).Type: ApplicationFiled: August 2, 2010Publication date: May 17, 2012Inventors: Manuela Kaspar, Christoph Schliemann, Dario Neri
-
Publication number: 20120121504Abstract: The invention relates to antibodies that are reactive to the cell surface of CD19+ B cells, including B-cell chronic lymphocytic leukemia (B-CLL) cells, and compositions and methods for using such antibodies, including in the diagnosis and treatment of disorders associated with CD19+ B cells, such as B-CLL.Type: ApplicationFiled: May 12, 2010Publication date: May 17, 2012Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human Svcs.Inventors: Christoph Rader, Sivasubramanian Baskar, Michael R. Bishop, Ivan Samija, Jessica M. Suschak
-
Publication number: 20120121503Abstract: A method of treating or reducing at least one inflammatory condition or the susceptibility to at least one inflammatory condition is provided involving administering at least one CD69 antagonist to a subject, wherein the subject has been diagnosed with at least one inflammatory condition, or a susceptibility to the same. CD69 antagonists can include one or more of an anti-CD69 antibody, an anti-CD69 aptamer, a CD69 mRNA antagonist, and a small molecule pharmaceutical.Type: ApplicationFiled: November 12, 2010Publication date: May 17, 2012Applicants: National University Corporation Yamaguchi University, National University Corporation Chiba UniversityInventors: Toshinori Nakayama, Akihiro Hasegawa, Mutsunori Shirai
-
Publication number: 20120114555Abstract: The present invention relates to the treatment of B-cell mediated immune disorders such as rheumatoid arthritis, systemic lupus erythromatomus, diabetes mellitus, and multiple sclerosis. In particular, the present invention relates to the treatment of B-cell mediated immune disorders using antibodies which bind to membrane-bound free light chain expressed on the surface of plasma cell precursors.Type: ApplicationFiled: April 7, 2010Publication date: May 10, 2012Applicant: IMMUNE SYSTEM THERAPEUTICS LTDInventors: Andrew T. Hutchinson, Darren R. Jones, Robert L. Raison, Parisa Asvadi, Rosanne D. Dunn
-
Publication number: 20120114556Abstract: Antibodies that bind with a B-cell antigen provide an effective means to treat autoimmune disorders. Antibodies and fragments, which may be conjugated or naked, are used alone or in multimodal therapies. The antibodies may be bispecific antibodies which may be produced recombinantly as fusion proteins, or as hybrid, polyspecific antibodies.Type: ApplicationFiled: January 13, 2012Publication date: May 10, 2012Applicant: IMMUNOMEDICS, INC.Inventors: David M. GOLDENBERG, Hans J. HANSEN
-
Publication number: 20120107234Abstract: The present invention is directed to improved therapeutics against receptors within the EGFR/ErbB/HER family that more broadly interfere with multiple members of the HER family (pan-HER inhibition). More particularly, the invention is directed to the use of antibody compositions for human cancer therapy. In vitro studies have shown that the antibody compositions of the invention targeting multiple HER family receptors are superior to antibody compositions targeting only one HER family receptor.Type: ApplicationFiled: November 1, 2011Publication date: May 3, 2012Inventors: Mikkel W. PEDERSEN, Ida K. CHRISTENSEN, Johan LANTTO, Helle JACOBSEN, Michael KRAGH
-
Publication number: 20120107235Abstract: The present invention provides humanized, chimeric and human anti-alpha-fetoprotein antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the treatment and diagnosis of hepatocellular carcinoma, hepatoblastoma, germ cell tumors carcinoma and other AFP-producing tumors.Type: ApplicationFiled: November 22, 2011Publication date: May 3, 2012Applicant: IMMUNOMEDICS, INC.Inventors: Hans J. Hansen, Zhengxing Qu, David M. Goldenberg
-
Publication number: 20120107233Abstract: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMAB of the instant invention.Type: ApplicationFiled: August 15, 2011Publication date: May 3, 2012Applicant: HOFFMANN-LA ROCHE INC.Inventors: David S.F. Young, Helen P. Findlay, Susan E. Hahn, Lisa M. Cechetto, Fortunata McConkey
-
Patent number: 8168184Abstract: The present invention relates to the treatment of immune system abnormalities that can be found in lethal human cancers and also in the progressive Human Immunodeficiency Virus Type 1 (HIV-1) infections and provides medicaments to correct abnormalities in a subject with cancer or HIV-1-infected subjects, in order to allow the immune system to fight the cancer or HIV-1 infections. The present invention also discloses multivalent polypeptides which specifically bind to and enable destruction and/or inactivation of immune cells that have CD11b and CD3 on their surface, therefore dissipating the deleterious effects of the CD11b+T cells.Type: GrantFiled: July 28, 2009Date of Patent: May 1, 2012Inventor: Robert Lamar Bjork, Jr.
-
Patent number: 8168586Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (“CAT”). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.Type: GrantFiled: November 21, 2008Date of Patent: May 1, 2012Assignee: Celera CorporationInventors: Dong Fang, Paul Moore, Steve Ruben, Sudeepta Aggarwal
-
Publication number: 20120100069Abstract: The present invention is related to a B-lymphocyte targeting agent for use in a method for the treatment or diagnosis of cardiac insufficiency. Furthermore, it is related to a composition comprising such B-lymphocyte targeting agent and methods for determining whether a patient suffering from cardiac insufficiency is amenable to the use of the B-lymphocyte targeting agent for its treatment.Type: ApplicationFiled: April 16, 2010Publication date: April 26, 2012Inventors: Carsten Tschöpe, H.P. Schultheiss, Felicitas Escher, Hans-Dieter Volk, Petra Reinke
-
Publication number: 20120093719Abstract: Antibodies (Ab) and antigen binding fragments capable of binding to prostate specific membrane antigen and which may be used for diagnostic and therapeutic purposes are provided herein. Formulation anti-PSMA antibodies which are stable under extreme storage condition are also provided.Type: ApplicationFiled: April 14, 2010Publication date: April 19, 2012Applicant: PROSCAN RX PHARMA INC.Inventors: Serge Moffett, Dominic Melançon, Uri H. Saragovi, Phil Gold, Claudio A. Cuello
-
Publication number: 20120087860Abstract: In another embodiment, a method for detecting and/or diagnosing a cancer in a subject is provided. The method may include administering an effective dose of a biotag to a subject, or alternatively, administering an effective dose of a targeted contrast to the subject, the targeted contrast comprising a contrast agent and a biotag as described herein for targeting a cancer biomarker. The method may further include exposing the subject to a diagnostic imaging technique; detecting a population of cells expressing the cancer biomarker; and quantifying the expression of the cancer biomarker in the population of cells, wherein an increased expression of the cancer biomarker indicates that the subject has cancer.Type: ApplicationFiled: May 24, 2011Publication date: April 12, 2012Inventors: Marek Malecki, Raf Malecki
-
Publication number: 20120087861Abstract: Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.Type: ApplicationFiled: October 11, 2011Publication date: April 12, 2012Inventors: Roger Nitsch, Feng Chen, Jan Grimm, Jean-Luc Baeriswyl, Christoph Hock
-
Patent number: 8153103Abstract: A new class of photoactivatable dyes provides the ability to study cell-cell communication in live animals non-invasively with high spatiotemporal resolution. The compositions are made up of a macromolecule, a caging group, and a coumarin dye. Upon photolysis, the coumarin dye is released from the macromolecule caging group complex and is freely diffusible in cells and between cells. The compositions are retained in cells very well, having no observable side effects, no susceptibility to metabolism, and the ability to generate bright fluorescence signals after photolysis. Because of their high loading capacity and long cellular retention, they can be selectively uncaged in specific cells.Type: GrantFiled: July 1, 2009Date of Patent: April 10, 2012Assignee: Board of Regents, The University of Texas SystemInventors: Wen-Hong Li, Yan-Ming Guo